Skyscape Web Viewer : Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs : Main Index

View All
programmed cell death protein 1 (PD-1) Answer 13.3 Immunotherapeutics Including Vaccines, Bispecifics, CAR-T, and Checkpoint Inhibitors Question 13.2 Question 13.3
progression-free survival (PFS) Answer 5.1 Answer 9.2 Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer Multiple Myeloma as a Paradigm for Multi-Targeted Intervention Targeted Therapies (Small Molecules)
progressive disease (PD)
progressive multifocal leukoencephalopathy (PML)
prostate cancer (PC) and rogens biosynthesis and rogens biosynthesis\|human prostate, sources of Answer 10.2 Answer 10.3 Answer 10.4 FDA-approved "hormonal" drugs Male Hormonal Therapies progression and treatment Question 10.2
prostate-specific antigen (PSA)
proteasome inhibitor (PI) Answer 14.4 immunomodulatory agents (IMIDS) Multiple Myeloma as a Paradigm for Multi-Targeted Intervention Question 14.4
proton pump inhibitors (PPIs)
PSA
PTCL
pulmonary embolism (PE)
PV
QTc
quiescence (G0)
Radioimmunoconjugates
RB
RECIST
recommended phase 2 dose (RP2D) Answer 16.1 Drug Approval and Regulatory Issues Question 18.1
reduced folate carrier (RFC)
refractory multiple myeloma (RRMM)
regulator of cullin 1 (Roc1)
regulatory T cells (Tregs)
response evaluation criteria in solid tumors (RECIST)
retinoblastoma (RB) DNA Repair, Apoptotic Pathways, CDK Inhibitors Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer
RFC
ribonucleotide reductase (RNR) inhibition polymorphism in thiopurine methyltransferase (TPMT) purine analogs
R-ICE
rituximab, ifosfamide, carboplatin, etoposide (R-ICE) Alkylating Agents Question 2.2
RNR
Roc1